Lenvatinib mesylate (E7080 mesylate),一种口服,多靶点酪氨酸激酶抑制剂,抑制血管内皮生长因子受体 (VEGFR1-3),成纤维细胞生长因子受体 (FGFR1-4),血小板衍生生长因子受体 (PDGFR),干细胞因子受体 (KIT),转染期间重排 (RET),显示有效抗癌的活性。
乐伐替尼甲磺酸盐
lè fá tì ní jiǎ huáng suān yán
更新时间:2024-04-15 22:11:25
- 常用名乐伐替尼甲磺酸盐英文名lenvatinib mesylate
- CAS号857890-39-2分子量522.959
- 密度N/A沸点N/A
- 分子式C22H23ClN4O7S熔点N/A
- MSDS闪点N/A
- 符号信号词
乐伐替尼甲磺酸盐 名称
- 中文名乐伐替尼甲磺酸盐
- 英文名lenvatinib mesylate
- 中文别名甲磺酸乐伐替尼 |乐伐替尼 |乐伐替尼甲磺酸盐 |甲磺酸仑伐替尼 |
- 英文别名4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide mesylate |Lenvatinib mesilate |lenvatinib mesylate |Lenvatinib mesylate [USAN] |4-{3-Chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxy-6-quinolinecarboxamide methanesulfonate (1:1) |4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate |4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide,methanesulfonic acid |6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, methanesulfonate (1:1) |Lenvatinib mesilate (JAN) |lenvatinib methanesulfonate |UNII-3J78384F61 |
乐伐替尼甲磺酸盐 生物活性
- 描述Lenvatinib mesylate (E7080 mesylate),一种口服,多靶点酪氨酸激酶抑制剂,抑制血管内皮生长因子受体 (VEGFR1-3),成纤维细胞生长因子受体 (FGFR1-4),血小板衍生生长因子受体 (PDGFR),干细胞因子受体 (KIT),转染期间重排 (RET),显示有效抗癌的活性。
- 相关类别研究领域 >> 癌症 信号通路 >> 蛋白酪氨酸激酶 >> PDGFR 信号通路 >> 蛋白酪氨酸激酶 >> FGFR 信号通路 >> 蛋白酪氨酸激酶 >> VEGFR 信号通路 >> 蛋白酪氨酸激酶 >> c-Kit
- 靶点VEGFR1:22 nM (IC50)VEGFR2:4 nM (IC50)VEGFR3:5.2 nM (IC50)FGFR1:46 nM (IC50)FGFR2FGFR3FGFR4PDGFRα:51 nM (IC50)PDGFRβ:39 nM (IC50)c-Kit:100 nM (IC50)RET
- 体外研究甲磺酸乐伐替尼(E7080甲磺酸酯)对VEGFR2(KDR),VEGFR3(Flt-4)和VEGFR1 / Flt-1的IC50分别为4,5.2,22nM。Lenvatinib分别以51,39,46,100nM的IC50抑制PDGFRα,PDGFRβ,FGFR1和KIT[3]。
- 体内研究甲磺酸Lenvatinib(E7080甲磺酸)(100mg/kg,p.o.)给药,贝伐单抗在m.f.p.显着抑制局部肿瘤生长,并且在治疗结束时,甲磺酸Lenvatinib也显着抑制局部淋巴结和远端肺的转移[3]。甲磺酸Lenvatinib(E7080甲磺酸盐)以剂量依赖性方式抑制30和100 mg/kg(BID,QDx21)下H146肿瘤的生长,并在H146异种移植模型中以100 mg/kg引起肿瘤消退。用抗CD31抗体进行IHC分析表明,与抗VEGF抗体和伊马替尼治疗相比,100 mg/kg的lenvatinib降低了微血管密度[4]。
- 参考文献[1]. Kudo M, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellularcarcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173. [2]. Suyama K, et al. Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers. Cancer Control. 2018 Jan-Dec;25(1):1073274818789361. [3]. 3.Matsui J, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008, 14(17),545. [4]. Matsui J, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008, 122(3), 664-671.
乐伐替尼甲磺酸盐 物理化学性质
- 分子式C22H23ClN4O7S
- 分子量522.959
- 精确质量522.097595
- PSA182.80000
- LogP5.81830
乐伐替尼甲磺酸盐 合成路线
共页
乐伐替尼甲磺酸盐 用途